tetano
Editor, Senior Moderator
Eur J Pharmacol
. 2020 Oct 29;173701.
doi: 10.1016/j.ejphar.2020.173701. Online ahead of print.
In silico identification of strong binders of the SARS-CoV-2 receptor-binding domain
Nouredine Behloul[SUP] 1 [/SUP], Sarra Baha[SUP] 2 [/SUP], Yuqian Guo[SUP] 1 [/SUP], Zhifang Yang[SUP] 3 [/SUP], Ruihua Shi[SUP] 4 [/SUP], Jihong Meng[SUP] 5 [/SUP]
Affiliations
Abstract
The world is currently witnessing the spread of the deadly severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes the coronavirus disease 2019 (COVID-19). In less than three months since the first cases were reported, the World Health Organization declared it a pandemic disease. Although several treatment and prevention strategies are currently under investigation, a continuous effort to investigate and develop effective cures is urgently needed. Thus, we performed molecular docking and structure-based virtual screening of libraries of approved drugs, antivirals, inhibitors of protein-protein interactions, and one million other small molecules to identify strong binders of the SARS-CoV-2 receptor-binding domain (RBD) that might interfere with the receptor recognition process, so as to inhibit the viral cellular entry. According to our screening and selection criteria, three approved antivirals (elbasvir, grazoprevir, and sovaprevir) and 4 other drugs (hesperidin, pamaqueside, diosmin, and sitogluside) were identified as potent binders of the RBD. The binding of these molecules involved several RBD residues required for the interaction of the virus with its cellular receptor. Furthermore, this study also discussed the pharmacological action of the 4 non-antiviral drugs on hematological and neurological disorders that, in addition to inhibiting the viral entry, could be beneficial against the neurological disorders identified in COVID-19 patients. Besides, six other small-molecules were identified, with no pharmacological description so far, exhibiting strong binding affinities to the RBD that we believe worth being investigated as inhibitors of the SARS-CoV-2-receptor interaction.
Keywords: COVID-19; Drug repurposing; Receptor-binding domain; SARS-CoV-2; Virtual screening.
. 2020 Oct 29;173701.
doi: 10.1016/j.ejphar.2020.173701. Online ahead of print.
In silico identification of strong binders of the SARS-CoV-2 receptor-binding domain
Nouredine Behloul[SUP] 1 [/SUP], Sarra Baha[SUP] 2 [/SUP], Yuqian Guo[SUP] 1 [/SUP], Zhifang Yang[SUP] 3 [/SUP], Ruihua Shi[SUP] 4 [/SUP], Jihong Meng[SUP] 5 [/SUP]
Affiliations
- PMID: 33130279
- DOI: 10.1016/j.ejphar.2020.173701
Abstract
The world is currently witnessing the spread of the deadly severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes the coronavirus disease 2019 (COVID-19). In less than three months since the first cases were reported, the World Health Organization declared it a pandemic disease. Although several treatment and prevention strategies are currently under investigation, a continuous effort to investigate and develop effective cures is urgently needed. Thus, we performed molecular docking and structure-based virtual screening of libraries of approved drugs, antivirals, inhibitors of protein-protein interactions, and one million other small molecules to identify strong binders of the SARS-CoV-2 receptor-binding domain (RBD) that might interfere with the receptor recognition process, so as to inhibit the viral cellular entry. According to our screening and selection criteria, three approved antivirals (elbasvir, grazoprevir, and sovaprevir) and 4 other drugs (hesperidin, pamaqueside, diosmin, and sitogluside) were identified as potent binders of the RBD. The binding of these molecules involved several RBD residues required for the interaction of the virus with its cellular receptor. Furthermore, this study also discussed the pharmacological action of the 4 non-antiviral drugs on hematological and neurological disorders that, in addition to inhibiting the viral entry, could be beneficial against the neurological disorders identified in COVID-19 patients. Besides, six other small-molecules were identified, with no pharmacological description so far, exhibiting strong binding affinities to the RBD that we believe worth being investigated as inhibitors of the SARS-CoV-2-receptor interaction.
Keywords: COVID-19; Drug repurposing; Receptor-binding domain; SARS-CoV-2; Virtual screening.